New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 25, 2014
08:31 EDTASMBAssembly Biosciences will not pursue further development of VEN 307
Assembly Biosciences announced that it will not pursue further development of VEN 307, an investigational product for the treatment of anal fissures. VEN 307 was being developed by Ventrus Biosciences prior to its recent merger with Assembly Pharmaceuticals. Post-merger, Assembly Biosciences is focused on development of its potentially curative programs for HBV and CDAD. At a meeting last month, the FDA indicated that it would consider accepting for review a New Drug Application for VEN 307, but that chances of approval were unclear without another clinical trial. As a result of this feedback and the shift in the company's strategic focus post-merger, management has decided to forego further investment in the VEN 307 program.
News For ASMB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ASMB

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use